![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, January 16, 2021 7:33:50 PM
conversation between the poster (FrankJ) and Les Goldman that took place yesterday.
According to the poster, the phase 3 statistical compilation is still ongoing apparently because it is much more complex and detailed than most of the public can imagine.
Furthermore, NWBO does not expect to use the 4 day notice for bad news because Les Goldman believes that the results will be be good. However, the fact that LG does not expect the 4 day notice to be used, implies that NWBO's statisticians have not even completed the statistical analysis and that TLD is still something in the future.
According to the Yahoo Board post, in anticipation of a positive outcome, NWBO is planning the preparation of a major paper and presentation at the right medical conference but with the statistical analysis not yet complete, how long will it be before we will live to see the publication, the conference or even TLD.
I am of course not certain that the Yahoo poster's interpretation of his conversation with LG is correct, but if it is, there is reason for concern. JMHO.
rankJ23 hours ago
I called Les Goldman and Dave Innes today. I got through to Les Goldman. We spoke for 14 minutes and covered a wide range of topics. Dave Innes also called me back shortly after speaking with Les.
The conversation with Les was very upbeat (I have attempted to capture the gist of our discussion and interject very little of my opinion or thoughts):
1) The phase 3 statistical compilation is ongoing; much more complex and detailed than most of the public can imagine........ there is no estimate of a completion date was provided
2) NWBO recognizes the four day bad news window and is legally obligated to abide by it; they do not expect to have to use this 4 day notice
3) The number of NWBO shareholders is growing and has grown dramatically over the last year
4) There are a number of institutional investors taking note in the company... firms and names not disclosed...nor did I ask for them.
5) Les is a Washing DC Football Team fan
6) Dr. Linda Liau presented in Boston at an important conference about 3 weeks ago, and it was very well received. There is growing interest in the Phase 3 study and associated outcome from a diverse number of parties. It is becoming much more widely recognized that NWBO's treatment extends life and is much, much more conducive to living well during the treatment period and thereafter.
7) The Sawston, Flaskworks, and Cognate Memphis partnerships/expansions are all real and happening.
8) In anticipation of a positive outcome, the company is working many aspects of anticipated success in parallel including preparation of a major paper and presentation at the right medical conference and using a prestigious medical journal ..... dependent on the timing and success of anticipated outcome.
9) Les and Dave Innes receive tons of calls from a wide realm of investors/interested parties. Many are short sellers striving to find any shred of negativity. They will give you the time of day if you are an interested involved sincere party.
Les sounded very sincere and willing to share as much as he could with me. I believe him. I currently own 140,000 shares of NWBO and have zero intention of selling any shares at any time soon. I do however have a limit order to sell 40,000 of those shares at $7.50/share.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM